These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19139114)

  • 1. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.
    Greenaway J; Henkin J; Lawler J; Moorehead R; Petrik J
    Mol Cancer Ther; 2009 Jan; 8(1):64-74. PubMed ID: 19139114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.
    Campbell NE; Greenaway J; Henkin J; Moorehead RA; Petrik J
    Neoplasia; 2010 Mar; 12(3):275-83. PubMed ID: 20234821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer.
    Campbell N; Greenaway J; Henkin J; Petrik J
    Mol Cancer Ther; 2011 Oct; 10(10):1876-85. PubMed ID: 21844212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.
    Russell S; Duquette M; Liu J; Drapkin R; Lawler J; Petrik J
    FASEB J; 2015 Feb; 29(2):576-88. PubMed ID: 25395453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
    Anderson JC; Grammer JR; Wang W; Nabors LB; Henkin J; Stewart JE; Gladson CL
    Cancer Biol Ther; 2007 Mar; 6(3):454-62. PubMed ID: 17384534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
    Matuszewska K; Ten Kortenaar S; Pereira M; Santry LA; Petrik D; Lo KM; Bridle BW; Wootton SK; Lawler J; Petrik J
    Gynecol Oncol; 2022 Jan; 164(1):154-169. PubMed ID: 34799137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombospondin-1 mimetic peptide ABT-898 affects neovascularization and survival of human endometriotic lesions in a mouse model.
    Nakamura DS; Edwards AK; Virani S; Thomas R; Tayade C
    Am J Pathol; 2012 Aug; 181(2):570-82. PubMed ID: 22727957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.
    Greenaway J; Moorehead R; Shaw P; Petrik J
    Gynecol Oncol; 2008 Feb; 108(2):385-94. PubMed ID: 18036641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells.
    Isenberg JS; Yu C; Roberts DD
    Biochem Pharmacol; 2008 Feb; 75(4):875-82. PubMed ID: 18068687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.
    Reiher FK; Volpert OV; Jimenez B; Crawford SE; Dinney CP; Henkin J; Haviv F; Bouck NP; Campbell SC
    Int J Cancer; 2002 Apr; 98(5):682-9. PubMed ID: 11920636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
    Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
    J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-lipoic acid modulates ovarian surface epithelial cell growth.
    Vig-Varga E; Benson EA; Limbil TL; Allison BM; Goebl MG; Harrington MA
    Gynecol Oncol; 2006 Oct; 103(1):45-52. PubMed ID: 16574204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model.
    Gutierrez LS; Ling J; Nye D; Papathomas K; Dickinson C
    World J Gastroenterol; 2015 May; 21(20):6157-66. PubMed ID: 26034351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compatibility of a novel thrombospondin-1 analog with fertility and pregnancy in a xenograft mouse model of endometriosis.
    Nakamura DS; Edwards AK; Ahn SH; Thomas R; Tayade C
    PLoS One; 2015; 10(3):e0121545. PubMed ID: 25811892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
    Haviv F; Bradley MF; Kalvin DM; Schneider AJ; Davidson DJ; Majest SM; McKay LM; Haskell CJ; Bell RL; Nguyen B; Marsh KC; Surber BW; Uchic JT; Ferrero J; Wang YC; Leal J; Record RD; Hodde J; Badylak SF; Lesniewski RR; Henkin J
    J Med Chem; 2005 Apr; 48(8):2838-46. PubMed ID: 15828822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease.
    Punekar S; Zak S; Kalter VG; Dobransky L; Punekar I; Lawler JW; Gutierrez LS
    Pathobiology; 2008; 75(1):9-21. PubMed ID: 18334835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
    Rusk A; McKeegan E; Haviv F; Majest S; Henkin J; Khanna C
    Clin Cancer Res; 2006 Dec; 12(24):7444-55. PubMed ID: 17189418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic delivery of a thrombospondin-1 mimetic decreases skeletal muscle capillarity in mice.
    Audet GN; Fulks D; Stricker JC; Olfert IM
    PLoS One; 2013; 8(2):e55953. PubMed ID: 23405239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.